- Portfolio Risk Analysis
- SuperGrowth MultiBaggers Blog SignUp
- What Makes Risk Research Different?
Apr. 21, 2021
Digital Turbine’s growth numbers are truly exceptional. In each of the last three quarters, the twelve month revenues and gross profit have grown at over 20% from the twelve month period ended three months later.
Apr. 19, 2021
ERIC produces telecommunications hardware including for 5G. With Nokia and Huawei, the company controls 80% of the markets it competes in.
Our selection for today, Aviat Networks, ranks 4 out of 61 on the list of high-momentum SuperGrowth MultiBaggers. Aviat Networks provides microwave transmission solutions for private networks and telecom providers.
Apr. 13, 2021
Freedom Holding Corp. is a fast-growing broker operating in Russia and Central Asia. It has developed a niche by allowing its customers the opportunity to participate in US IPOs.
Apr. 07, 2021
Zoom is the most profitable, fastest growing of all SuperGrowth MultiBaggers. In fact, it is the most profitable of all public companies
Mar. 29, 2021
SFM was up 16.35%, the most of any SuperGrowth MultiBagger this week, whether a Current Position or on the Potential Positions list. It is about 4% of the Risk Research portfolio, and was purchased February 2nd at $21.39, versus the current $28.33. The Algo-indicated BuyAt and SellAt levels are $23.06 and $28.46 respectively, so only a few pennies away from being sold.
Mar. 25, 2021
Companies go off and on the list for various reasons. One common reason is they go up so much in price that their five-year appreciation potential appears diminished.
Feb. 25, 2021
The crucial element is position size. By taking small positions, an investor can afford to wait out the initial unprofitable trades and have sufficient liquidity to capitalize on the subsequent opportunities.
Feb. 19, 2021
Rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, including, among many other tests, tests for COVID-19. Quidel’s diagnostic tests are almost as accurate as tests that take much longer to process.
Feb. 18, 2021
A logistics business, servicing CAR-T and gene-based therapy innovators. Provides strict temperature-controlled transport of biological specimens to ensure their livelihood, efficacy, and safety.
Feb. 17, 2021
Yesterday sold half of my remaining CRM position at $250. Purchased at an average of $222.22 from November 25 to Dec 22. Current indicated SellAt price $257.14. Current stock price $246.95. The stock was strong yesterday due to its positions in two highly promising investments — Snowflake and Databricks.
Feb. 12, 2021
In reality, the Risk Research actually holds a position in CRM with an average cost of $222.22, 10.2% of portfolio. That’s after selling half our position February 2 at $234.54.
Feb. 11, 2021
Purchased QLYS this morning at $100.675. Indicated BuyAt price of $109.14. Current market $104.92. The stock is weak this morning despite strong Q4 results on the forecast that the rest of the year may be below expectations.
Feb. 10, 2021
Up until roughly a month ago, we were ignoring most SellAt signals. Due to the current market level, we are now taking advantage of those.
Feb. 09, 2021
Every so often the Algo generates buy or sell signals that just don’t look right. I watch carefully for these because they are not only dangerous, but once figured out can inspire Algo modifications that prove particularly significant and profitable.
Feb. 05, 2021
PDEX is an interesting company — manufacturer of customized surgical and other tools — now going through a short-term earnings decline.
Feb. 04, 2021
One stock, QLYS, is close to its indicated BuyAt price. I took a 3% of portfolio position yesterday at $123.18. I’ll buy more today at $120.59 should it decline to that level.
Feb. 03, 2021
Note that these three trades generated an average profit of 11.3%, with an average holding period of 0.4 months (just under 2 weeks), generating an annualized return of just under 357%.
Feb. 02, 2021
Sold ADBE $481.37. This was a substantial position — 20% of portfolio — bought at average price of $469 in the first week of January. Cash position now 42% of portfolio.
Feb. 01, 2021
The Risk Research portfolio for the month of January was down 0.08%. The S&P 500 was down 0.01%. The Risk Research portfolio performance was hindered by large positions in ADBE and CRM — positions totalling roughly 35% of portfolio.
Jan. 29, 2021
This is the stock that retail investors on Reddit chose to challenge hedge funds with.
Jan. 29, 2021
In the last twelve months, Weis’s free cash flow is up 364% on an increase in revenue of 14%.
Jan. 27, 2021
Purchases and sales made at the Algo-indicated prices would have generated a return of just under 30% per transaction, average holding time of 1.2 months, return annualized of 287%.
Jan. 26, 2021
The AI Algo, when applied to BIO, generated returns of 56.5% per position, with a holding period averaging 1.6 months, which extrapolates to an annual return of just over 434%.
Jan. 22, 2021
Progressive is one of the more stable SuperGrowth MultiBaggers in both free cash flow and stock price volatility, which, over time, tend to mirror each other.
Jan. 21, 2021
Nothing is within one percent of either the Algo-indicated Buy At or Sell At prices. Two are within 2% of their indicated Sell At price, NVDA and CRM. We’re looking forward to selling part of the CRM position and all of the NVDA position should they reach those prices today.
Jan. 20, 2021
Today’s charts, the hourly prices of SPY (the S&P 500 ETF) and XLF (large banks and insurance companies including Berkshire Hathaway) since December 7.
Jan. 19, 2021
This morning, Advanced Micro Devices (AMD) was selected based on its proximity to the AI indicated Buy At price, and the company’s dramatically improving financial performance over the last year.